GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Shiller PE Ratio

Cidara Therapeutics (Cidara Therapeutics) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cidara Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cidara Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Shiller PE Ratio Chart

Cidara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cidara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cidara Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Cidara Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Shiller PE Ratio falls into.



Cidara Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cidara Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cidara Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.2/129.4194*129.4194
=-1.200

Current CPI (Dec. 2023) = 129.4194.

Cidara Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -4.613 99.695 -5.988
201406 -21.003 100.560 -27.031
201409 -21.655 100.428 -27.906
201412 -7.325 99.070 -9.569
201503 -10.614 99.621 -13.789
201506 -11.800 100.684 -15.168
201509 -13.400 100.392 -17.275
201512 -14.400 99.792 -18.675
201603 -14.200 100.470 -18.292
201606 -17.000 101.688 -21.636
201609 -17.600 101.861 -22.362
201612 -17.600 101.863 -22.361
201703 -16.000 102.862 -20.131
201706 -19.800 103.349 -24.795
201709 -14.600 104.136 -18.145
201712 -13.800 104.011 -17.171
201803 -16.000 105.290 -19.667
201806 -22.600 106.317 -27.511
201809 -9.800 106.507 -11.908
201812 -8.800 105.998 -10.744
201903 -11.600 107.251 -13.998
201906 -9.400 108.070 -11.257
201909 1.600 108.329 1.911
201912 -8.400 108.420 -10.027
202003 -9.200 108.902 -10.933
202006 -9.000 108.767 -10.709
202009 -8.200 109.815 -9.664
202012 -9.800 109.897 -11.541
202103 -7.800 111.754 -9.033
202106 3.600 114.631 4.064
202109 -7.400 115.734 -8.275
202112 -5.200 117.630 -5.721
202203 -5.400 121.301 -5.761
202206 -3.800 125.017 -3.934
202209 3.400 125.227 3.514
202212 -3.800 125.222 -3.927
202303 0.600 127.348 0.610
202306 -2.800 128.729 -2.815
202309 -1.800 129.860 -1.794
202312 -1.200 129.419 -1.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cidara Therapeutics  (NAS:CDTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cidara Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics (Cidara Therapeutics) Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121

Cidara Therapeutics (Cidara Therapeutics) Headlines

From GuruFocus

Cidara Therapeutics to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 03-31-2023